Last Updated: 14 Sep 2024
Executive Summary
Atea Pharmaceuticals Inc. (AVIR) is a clinical-stage biopharmaceutical company focused on antiviral therapies. With a market capitalization of $309.8 million, the company has shown revenue growth but remains unprofitable. Analysts hold mixed views, with one strong buy rating, one hold rating, and one sell rating. The stock's current price of $3.87 is within its 52-week range and below its analyst target price of $6.88.
Company Overview
Headquartered in Boston, Massachusetts, Atea Pharmaceuticals is developing antiviral therapies for viral infections. The company's pipeline includes candidates for the treatment of COVID-19, influenza, and other respiratory viruses. Atea has partnered with Roche and Merck to advance its clinical programs.
Fundamental Analysis
Revenue: Revenue for the trailing twelve months (TTM) was $192.2 million, reflecting a 2.95% year-over-year growth.
Earnings: Atea continues to operate at a loss, with a diluted EPS of -$2.1 for the TTM.
Margins: Gross profit margin is negative at -42.6%, indicating high operating expenses.
Valuation: The stock trades at a price-to-sales ratio of 1.90 and a price-to-book ratio of 0.65.
Technical Analysis
Trend: The stock has been trading within a range between $2.76 and $4.6 over the past 52 weeks.
Moving Averages: The 50-day moving average is currently at $3.63, while the 200-day moving average is at $3.67.
Support and Resistance: Support levels are seen around $3.50, while resistance is expected at $4.00.
Short Term Outlook
In the short term, Atea's stock may continue to trade within its current range. The company's upcoming clinical data releases and partnership updates could provide catalysts for movement.
Long Term Outlook
The long-term outlook for Atea depends on the success of its clinical programs and its ability to commercialize its therapies. If the company can successfully develop and launch effective antiviral treatments, it could see significant growth potential.
Analyst Recommendations
Analysts have mixed views on Atea Pharmaceuticals:
Strong Buy: 1
Buy: 0
Hold: 1
Sell: 1
Strong Sell: 0
The average analyst target price is $6.88, implying a potential upside of 78% from the current price.
